Metabolic Access

Tag: ulcerative colitis

  • Butyrate for Pediatric IBD: Why Two Trials Reached Different Answers

    Two studies of butyrate for pediatric IBD can leave parents with opposite impressions. One found no added benefit; another reported a much higher remission rate. The best response is not to choose the more reassuring headline, but to compare what was actually tested.

    Butyrate and IBD evidence series · Part 3 of 3
    Published: September 28, 2026 · Last updated: September 28, 2026

    Quick answer

    The evidence is conflicting and does not establish a routine butyrate treatment or dose for children with IBD. Both trials added oral sodium butyrate to conventional care; neither tested a replacement for it. The positive result deserves follow-up, while reporting problems and the earlier negative result remain relevant. 2022 trial; 2025 trial.

    Key takeaways for parents

    • These are studies of sodium butyrate, not live butyrate-producing probiotics.
    • A study’s remission percentage is not your child’s personal probability of success.
    • Comparing different studies cannot identify the better dose.
    • Symptoms, inflammation, nutrition, growth, and longer-term control all matter to the clinical conversation.

    Butyrate for pediatric IBD: the two trials side by side

    The table describes research regimens so readers can distinguish the trials. Do not use these doses to start or adjust a child’s supplement. Both studies included newly diagnosed Crohn’s disease and UC.

    Research comparison, not a dosing guide; swipe on a phone
    Question2022 Polish trial2025 Romanian trial
    Design and analysisMulticenter, randomized, placebo-controlled; 72 analyzed.Single-center, randomized, placebo-controlled; 88 completed.
    Research regimen150 mg twice daily, 12 weeks, alongside standard care.150 mg once daily, 12 weeks, alongside standard care.
    Reported remission62% with butyrate vs. 72% with placebo; p=0.371.36/44 (81.82%) vs. 21/44 (47.73%).
    Main interpretive issueNo demonstrated added benefit; incomplete follow-up and uneven analyzed groups.Positive signal, with inconsistencies between tables and narrative.

    Sources: 2022 full text and 2025 original paper. We did not pool their results.

    What the negative study does—and does not—mean

    The 2022 analysis included 29 children receiving butyrate and 43 receiving placebo. Neither remission nor fecal-calprotectin results established an added benefit. The paper describes 80 included patients, nine incomplete records, and 72 analyzed—a flow-reporting inconsistency worth noting. Results and participant flow.

    A null result is not proof that no child could ever benefit. Equally, improvement in the treated group is not proof the supplement caused it: both groups received conventional care. The relevant question is whether adding the intervention improved outcomes relative to the comparison.

    How confidently can we interpret the positive study?

    The 2025 paper reports a substantial difference. However, Table 4 lists 23 UC patients in Group A and 25 in Group B, while the following narrative reverses those totals. We checked the table and paragraph in the original PDF. This does not establish that the entire trial is invalid; it does mean the report needs clarification before readers lean heavily on subgroup claims. Goldiș et al., Table 4 and accompanying text.

    Replication is especially useful when a strong result differs from earlier work. A new, clearly reported trial can test whether the signal persists across settings. Until then, uncertainty should remain visible beside the encouraging finding, not buried in a footnote.

    Why the lower dose cannot be called the better dose

    The two studies did not randomize comparable children within one trial to two dose levels. They also differed in setting, participant mix, and potentially other aspects of care and measurement. Thus, their contrast cannot identify a dose-response relationship. This is our interpretation of their designs, not a mechanism demonstrated by either study.

    Imagine comparing two schools that used different textbooks and also had different teachers, students, and class sizes. A difference in test scores would not isolate the textbook. The same logic applies here: changing several conditions at once prevents a clean explanation based on dose alone.

    It would also be inappropriate to calculate a child’s regimen from adult trials. Pediatric IBD is not simply adult IBD with a smaller body weight. Growth and development can be affected by the disease, and those needs belong in treatment planning. NIDDK: UC and childhood complications.

    What “remission” leaves unanswered

    A remission endpoint describes a defined state at a particular assessment. It does not automatically tell a family whether a child will remain well through the next school year, reach expected growth milestones, or avoid a future treatment change. Ask the team which outcomes are most important for your child, and how they will be measured.

    Likewise, symptoms and objective inflammation deserve separate attention. Blood tests, stool testing, and endoscopy contribute different information to IBD assessment. A child feeling better is meaningful, but it is not a reason to cancel planned clinical follow-up without discussing it. NIDDK: assessment and testing.

    A parent’s appointment worksheet

    Bring a short, factual note rather than a stack of product advertisements. This template is for discussion; it does not assume that supplementation will be appropriate.

    1. Our question: “Could this add anything to the current plan, and what evidence would apply to our child?”
    2. Current context: diagnosis, recent symptoms, medicines, other supplements, and any recent changes in eating or growth.
    3. The exact product: a photo of the full label, including formulation, ingredients, and serving information. Highlight whether it contains sodium butyrate or live organisms.
    4. The expected outcome: ask whether the goal concerns symptoms, inflammation, nutrition, or something else. Avoid a vague target such as “better gut health.”
    5. The assessment plan: who reviews progress, when contact is needed, and what findings would lead to stopping or avoiding the product.
    6. The alternative: ask what the team would prioritize instead if evidence is insufficient. Doing nothing new while following an effective plan is also a decision.

    A useful question is: “What new information would change your recommendation?” It invites a discussion about uncertainty without pressuring the clinician to endorse a supplement or dismiss research prematurely.

    Food, fiber, and nutrition are not interchangeable with a capsule

    The AGA’s nutrition guidance supports individualized food advice and dietitian involvement in complicated IBD. It distinguishes a generally healthful eating pattern from specific therapeutic nutrition approaches and notes that strictures may require changes in food texture. These principles do not translate into telling every child to increase fiber aggressively. AGA diet and nutritional therapy guidance.

    Ask a pediatric GI clinician and dietitian about adequate energy, tolerated foods, and growth. Do not introduce major food exclusions or a high-dose fiber product merely to increase a microbial metabolite. Our SCFA and fiber guide explains the biology, but it is not a pediatric feeding prescription.

    Safety questions worth asking

    For products sold as dietary supplements in the US, FDA does not review and approve safety and effectiveness before marketing. A product being available online does not establish suitability for a child with IBD. Discuss its full label with the care team; do not substitute it for prescribed treatment. FDA supplement guidance.

    Live probiotic products raise a separate question. NCCIH notes greater potential for harmful effects in people with severe illnesses or compromised immune systems. That warning should not be transferred mechanically to a nonliving butyrate compound, but neither should one category borrow the other’s safety record. NCCIH probiotic safety information.

    If a child develops worsening bleeding, severe pain, marked weakness, or difficulty staying hydrated, seek medical assessment rather than testing a supplement first. Severe IBD complications can require hospital care. NIDDK complication guidance.

    Frequently asked questions

    Is butyrate for pediatric IBD ready for routine use?

    The studies reviewed here do not establish a dependable routine regimen. A pediatric specialist can discuss whether further research or any individualized consideration is appropriate.

    Do these studies validate a butyrate-producing probiotic?

    No. The trial ingredient and a living strain are different interventions. See the probiotic and pouchitis evidence review for that distinction.

    Should we follow the adult research instead?

    Adult findings provide research context, not a child’s treatment plan. Our adult UC review keeps that evidence separate.

    Bottom line

    Interest in butyrate for pediatric IBD is reasonable. Confidence in a child-specific benefit or dose is a different matter. Keep both trials in view, ask for better reporting and replication, and make practical decisions with the team responsible for the child’s ongoing care.

    Sources and further reading

    1. Pietrzak et al. Pediatric randomized multicenter trial, 2022.
    2. Goldiș et al. Pediatric IBD trial, 2025. PubMed record.
    3. AGA diet and nutritional therapies guidance, 2024.
    4. NIDDK: UC facts and complications.
    5. FDA: consumer supplement information.

    Methods, limits, and transparency

    This is a focused narrative comparison, not a systematic review or pooled analysis. We checked the two trial reports, including the 2025 paper’s Table 4 and adjacent narrative, and relevant US guidance on September 28, 2026. However, this review does not include individual patient data or clarification from the study authors. It separates reported results from our interpretation; it is not an exhaustive review of pediatric IBD therapies.

    Adapted from the Korean-language Aether Health review, with a parent-focused US discussion guide and an additional participant-flow caveat. English primary sources above make this edition self-contained.

    Disclosure: Prepared with AI assistance; no independent medical or scientific review is claimed for this English edition. The Korean edition records the operator’s September 24, 2026 disclosure of no current financial interest in related butyrate/SCFA ingredient or product companies. No purchase or affiliate links are included.

    Update history: September 28, 2026 — First English edition; inconsistent reporting and limits of cross-trial dose comparisons highlighted.

    Written and edited by: Denny Jaeyong Choi (JD), INSEAD MBA

    Medical information notice: General education, not a child’s diagnosis, prescription, or dose recommendation. Consult a qualified pediatric clinician before supplement use or treatment changes.

  • Butyrate Probiotics and Pouchitis: Why the Exact Strain and Treatment Goal Matter

    Looking for probiotics for pouchitis can lead to a confusing mix of bacterial names, “butyrate support” claims, and studies of ordinary ulcerative colitis. Before comparing products, identify the problem the study was actually trying to prevent or treat.

    Butyrate and IBD evidence series · Part 2 of 3
    Published: September 28, 2026 · Last updated: September 28, 2026

    Quick answer

    US guidance distinguishes preventing a first episode, treating an active episode, and preventing recurrence after antibiotics. Its conditional support for probiotics in recurrent, antibiotic-responsive pouchitis is not an endorsement of every butyrate-producing strain. AGA pouchitis guideline, 2024.

    Key takeaways

    • A pouch is surgically created bowel anatomy, not another name for the colon.
    • Evidence for a specific strain cannot automatically be transferred to another strain or a multi-organism blend.
    • A favorable early time point does not prove year-long relapse prevention.
    • A probiotic and an oral butyrate salt are different interventions.

    Why the pouch changes the question

    After removal of the colon and rectum, some people with UC have an ileal pouch–anal anastomosis, or IPAA. Surgeons use small intestine to make a reservoir. Inflammation of that reservoir is pouchitis. This differs from treating inflammation in an intact colon. The AGA’s overview of pouch disorders explains the clinical setting.

    Therefore, “helped patients who originally had UC” is not enough information. Ask whether they still had their colon, had a pouch without previous inflammation, or had recurrent episodes after treatment. Those are different groups with different clinical decisions.

    Probiotics for pouchitis: three separate decisions

    AGA 2024 guidance; swipe horizontally on a phone
    Clinical questionProbiotic recommendationDo not confuse it with
    Prevent a first episode after IPAANo recommendation for or against; evidence gap.Prevention of recurrent episodes.
    Treat active pouchitisNo recommendation for or against probiotics.An alternative to indicated treatment.
    Prevent recurrence after antibiotic responseConditional suggestion in favor.Approval of any probiotic on the shelf.

    The recurrence trials used the De Simone multi-strain formulation. That detail matters: it is not a general recommendation for Clostridium butyricum. Cost and treatment burden can also make choosing no preventive probiotic reasonable for some patients. Decisions belong with the pouch-care team. AGA recommendations and implementation notes.

    What did the butyrate-producing strain trial find?

    Yasueda and colleagues reported a randomized placebo-controlled trial of C. butyricum MIYAIRI in 17 people after IPAA. Pouchitis occurred in 1 of 9 assigned the probiotic and 4 of 8 assigned placebo. The abstract reports no side effects in either group. Original trial abstract, published 2016.

    That is an encouraging direction, but a small number of events. One or two additional cases would substantially change the apparent benefit. It also answers a prevention question in postoperative patients—not whether a different strain treats an active UC flare. We reviewed the abstract rather than the full protocol, so do not derive a detailed treatment schedule or a long-term safety guarantee from this summary.

    What does BIO-THREE add to the UC evidence?

    An early uncontrolled study

    A 2007 report treated 20 adults with active distal UC using BIO-THREE, a three-organism preparation. After four weeks, nine were in remission and two more had a response. However, there was no control group. The contribution of the preparation cannot be separated reliably from background care or the disease’s course. Nor can a blend’s result be assigned to its butyrate-producing component alone. Tsuda et al.

    A longer randomized study gave a less decisive answer

    The 2015 maintenance trial randomized 60 people with inactive UC, but analyzed 46 after exclusions. At three months, reported relapse was 0% with BIO-THREE versus 17.4% with placebo. At 12 months, cumulative remission maintenance was 69.5% versus 56.6%. The overall log-rank comparison was not significant (p=0.302). Yoshimatsu et al., full report.

    Our interpretation is deliberately narrower than “prevents relapse.” Selecting only the first positive time point hides the longer follow-up. Conversely, a nonsignificant finding does not prove the true effect is exactly zero. The uncertainty is the conclusion, not an inconvenience to remove from the headline.

    Why ordinary UC guidance can differ from pouchitis guidance

    The AGA’s 2020 probiotic guideline recommends use in adults and children with UC or Crohn’s only in a clinical-trial setting. The ACG’s 2025 UC guidance also finds insufficient evidence to recommend probiotics for maintenance as primary or adjunctive treatment. These positions concern particular clinical questions, not the idea that microbes can never matter. AGA probiotic guidance; ACG adult UC guidance.

    For pouch-related decisions, the newer, dedicated 2024 guideline above provides more specific context. A general webpage saying probiotics “help UC” can miss this distinction. Likewise, a guideline about live microorganisms does not directly settle the evidence for a sodium-butyrate preparation.

    How to evaluate probiotics for pouchitis before spending money

    Make a one-page comparison rather than a shopping list. Put the paper’s intervention on one side and the product label on the other. Mark unknown details as unknown; do not fill them in from a similar-sounding name.

    1. Match the organism or formulation. Record strain identifiers and every organism in a blend. Species names alone are not a complete match.
    2. Match the setting. Write “first-episode prevention,” “active treatment,” or “recurrence prevention.” If the claim changes setting midway, ask why.
    3. Match the outcome and period. Symptom relief, an inflammation score, and a year without relapse are not interchangeable.
    4. Ask about practical delivery. Check the studied dose, product viability and storage information with the clinician or pharmacist; a large front-label count is not proof of equivalence.
    5. Agree on a review point. Ask what benefit would justify continued cost and what worsening symptoms should trigger contact with the care team.

    These checks follow the AGA’s emphasis on strain identity, formulation, harms reporting, and treatment burden when reading probiotic trials. AGA: how to assess a probiotic study.

    Safety is part of the decision

    “Live bacteria” and “butyrate” should not share one generic safety statement. NCCIH notes that harmful effects from probiotics are more likely in people with severe illness or compromised immune systems. Tell your clinician about immune-suppressing treatment and other major health problems before using a live-microorganism product. Small trials with no reported adverse events cannot exclude rare harms. NCCIH probiotic safety information.

    Do not use a probiotic to delay assessment of new or worsening pouch symptoms. The AGA suggests antibiotics for intermittent pouchitis, while frequent or treatment-resistant problems require a different assessment and care pathway. This is context for a clinical discussion, not instructions to obtain antibiotics yourself. AGA treatment overview.

    Frequently asked questions

    Does making butyrate mean a strain will prevent pouchitis?

    No clinical conclusion follows from that property alone. A proposed mechanism helps choose what to test; patient outcomes determine whether it worked in the tested setting.

    Can I substitute a butyrate capsule for a probiotic?

    Not on the basis of these trials. See our separate adult oral-butyrate review. Similar terminology does not make the interventions equivalent.

    Is more expensive or higher-count necessarily better?

    Those features do not establish a match with the evidence. Ask which precise formulation has relevant clinical data and whether the likely benefit justifies the expense. We do not rank brands or verify coverage here.

    Bottom line

    The most useful question about probiotics for pouchitis is not “Which gut-health product is strongest?” It is “Which tested formulation addresses my particular treatment goal?” Keeping anatomy, strain, and outcome separate makes both positive and negative research more useful.

    Sources and further reading

    1. AGA Clinical Practice Guideline on Pouchitis, 2024.
    2. Yasueda et al. MIYAIRI pouchitis trial, 2016.
    3. Tsuda et al. BIO-THREE exploratory study, 2007.
    4. Yoshimatsu et al. UC relapse-prevention trial, 2015.
    5. AGA probiotic guideline, 2020.
    6. NCCIH: Probiotics, Usefulness and Safety.

    Methods and transparency

    This focused narrative review is not a systematic review or meta-analysis. Evidence checked September 28, 2026: Yasueda and Tsuda abstracts, Yoshimatsu full-text results, AGA recommendation passages, ACG guidance, and NCCIH safety information. We did not verify every commercial product or conduct a new pooled analysis. The guideline context is US-focused; study preparations may not match US retail products.

    Adapted from the Korean-language review at Aether Health, with US pouchitis guidance added. Also see the pediatric evidence review and our SCFA background guide.

    Disclosure: Prepared with AI assistance; no independent medical or scientific review is claimed for this English edition. The Korean edition records the operator’s September 24, 2026 disclosure of no current financial interest in related butyrate/SCFA ingredient or product companies. There are no purchase or affiliate links.

    Update history: September 28, 2026 — First English edition; primary prevention, active treatment, and recurrence prevention separated.

    Written and edited by: Denny Jaeyong Choi (JD), INSEAD MBA

    Medical information notice: Education only, not diagnosis, prescribing, or a recommendation to change treatment. Consult your GI team about personal care.

  • Butyrate for Ulcerative Colitis: What the Clinical Trials Really Show

    Research on butyrate for ulcerative colitis has moved beyond a plausible gut-health mechanism. The useful question is now more specific: can a particular oral preparation improve a meaningful outcome when added to established treatment?

    Butyrate and IBD evidence series · Part 1 of 3
    Published: September 28, 2026 · Last updated: September 28, 2026

    Quick answer

    A placebo-controlled adult trial supports a promising, short-term add-on role for microencapsulated sodium butyrate in mild-to-moderate UC. It does not establish that every butyrate product heals the bowel or prevents relapse. Read clinical remission separately from endoscopic remission, and keep standard treatment in place. 2025 randomized trial.

    Key takeaways

    • Butyrate is a compound; a butyrate-producing probiotic is a living organism. Their evidence is not interchangeable.
    • Improvement, remission, and long-term disease control are different outcomes.
    • A positive controlled trial deserves attention, without turning its result into a product-wide promise.
    • Newer Crohn’s research means the evidence should not be described as only a small 2005 pilot.

    What was tested in the 2025 UC trial?

    Karłowicz and colleagues randomized 107 adults to existing treatment plus microencapsulated sodium butyrate, 300 mg twice daily, or placebo for eight weeks. These are research conditions, not dosing instructions. The table uses intention-to-treat (ITT) results, with the originally assigned groups as denominators. Original report.

    Eight-week ITT results; swipe horizontally on a phone
    OutcomeButyrate addedPlacebo added
    Clinical remission16/54 (29.6%)3/53 (5.7%)
    Clinical improvement26/54 (48.1%)10/53 (18.9%)

    The remission difference was about 24 percentage points. However, endoscopic remission did not differ significantly. Endoscopy was assessed without blinding, and follow-up was short. Polpharma supplied the study preparations. The report’s biochemical-remission threshold was fecal calprotectin ≤250 µg/g, not a universal definition of a normal result. The abstract emphasizes 98 participants with follow-up; do not mix those percentages with the ITT denominators above. Methods, results, and limitations.

    How to read a claim about butyrate for ulcerative colitis

    Try translating a headline into a complete sentence: “In these patients, this preparation, added to this background care, changed this outcome over this period.” If any part is missing, the claim is harder to apply.

    In particular, keep these questions separate:

    • Did symptoms improve? This matters to everyday life, but is not the only treatment goal.
    • Did a disease-activity score meet the trial’s remission threshold? “Remission” is a defined state, not a synonym for cure.
    • Did the bowel lining improve on examination? An endoscopic result addresses a different question from how someone feels.
    • Did control last? A short intervention cannot supply years of follow-up.

    The ACG’s 2025 adult UC guidance emphasizes effective induction and maintenance care and objective disease assessment. An interesting adjunct does not remove the need for that framework. Also, guidance about probiotics should not be misquoted as a direct evaluation of an oral butyrate salt.

    Does butyrate help maintain UC remission?

    A 2020 prospective observational study by Vernero and colleagues enrolled 42 people already in remission; 39 completed follow-up. At 12 months, its combined therapeutic-success endpoint—partial Mayo score ≤2 plus fecal calprotectin <250 µg/g—was met by 15/18 receiving added butyrate and 10/21 receiving standard mesalamine alone. That is 83.3% versus 47.6%. Original study abstract.

    The distinction is important: these were not randomly assigned groups. Treatment selection and other differences may help explain the association. This is a reason to conduct stronger maintenance trials, not proof of a reliable relapse-prevention benefit. Nor should its combined endpoint be relabeled simply as “complete healing.”

    What about Crohn’s disease?

    The early Di Sabatino study gave enteric-coated butyrate to 13 adults with mild-to-moderate ileocolonic Crohn’s disease for eight weeks. Nine responded, including seven who reached remission. However, there was no control group. Those counts cannot tell us what would have happened without the intervention. 2005 pilot abstract.

    A later randomized pilot included 49 adults: 19 with Crohn’s and 30 with UC. Its two-month investigation focused on microbiota changes, with a quality-of-life signal in UC. A change in bacterial composition is not itself proof of Crohn’s remission. Facchin et al., 2020.

    A newer trial changes the evidence map—not the need for caution

    A 2026 publication reports a randomized, double-blind, placebo-controlled trial involving 140 people: 60 with Crohn’s and 80 with UC. The abstract reports improvements in Crohn’s disease activity and fecal calprotectin, as well as quality of life in both diagnoses. It also explores microbiome-defined subgroups. Facchin et al., 2026.

    We verified the abstract, not the complete dataset. It does not provide enough detail to derive an absolute remission benefit or confidently classify every reported comparison as between-group rather than within-group. We therefore do not calculate a treatment-success probability from its p-values. This larger study belongs in the discussion, but a microbiome subgroup is not yet a validated consumer test for choosing a supplement.

    A practical appointment checklist

    Instead of asking only “Should I buy butyrate?”, take the following information to your GI team. The aim is a decision you can evaluate, rather than an open-ended supplement experiment.

    1. Confirm the clinical question. Are you treating current symptoms, investigating inflammation, or discussing maintenance after remission? Write down the goal in one sentence.
    2. Bring the exact label. Record the ingredient, formulation, amount per serving, other ingredients, and manufacturer. A familiar word on the front is not enough to match a trial.
    3. List current treatment. Include prescribed medicines, nonprescription products, and recent changes. Ask whether any proposed addition would interfere with the existing plan.
    4. Agree on follow-up. Ask which symptoms or tests would be informative, who will review them, and what would lead to stopping the product.
    5. Discuss cost before committing. Ask whether the expected information or possible benefit justifies an ongoing out-of-pocket expense. This review does not establish US insurance coverage.

    FDA does not approve dietary supplements for safety and effectiveness before they reach the market. A supplement label or an ingredient paper is not proof of FDA approval to treat UC. FDA consumer guidance.

    When care matters more than supplement selection

    Do not reduce or stop prescribed IBD treatment because of these results. Contact your GI team for worsening bleeding, diarrhea, pain, or difficulty maintaining food and fluid intake. Severe pain, heavy bleeding, faintness, or signs of serious dehydration warrant urgent medical assessment. UC can cause complications that require hospital care. NIDDK: complications of UC.

    Frequently asked questions

    Is butyrate the same as a butyrate-producing probiotic?

    No. One supplies a compound; the other supplies living microorganisms. Our probiotics and pouchitis review explains why strain and surgical context matter.

    Can a generic capsule borrow a trial’s results?

    A match requires more than the word “butyrate.” Ask whether the tested formulation, population, background treatment, and outcome match the claim. We have not verified equivalence between the study preparations and every US retail product.

    Can adults’ results guide a child’s dose?

    No. Children need their own evidence and clinical assessment. See our comparison of pediatric butyrate trials; it is not a dosing guide.

    Bottom line

    Butyrate for ulcerative colitis is a legitimate research question, not just a marketing story. The responsible interpretation preserves both the encouraging findings and the limits. Bring the evidence to a clinical conversation; do not convert it into a substitute treatment plan.

    Sources and further reading

    1. Karłowicz et al. Adult UC randomized trial, 2025.
    2. Vernero et al. UC maintenance observational study, 2020.
    3. Di Sabatino et al. Crohn’s pilot, 2005.
    4. Facchin et al. IBD microbiota pilot, 2020.
    5. Facchin et al. Larger IBD randomized trial, 2026.
    6. ACG: 2025 adult UC guideline summary.

    How this review was prepared

    This is a focused narrative review, not a systematic review or meta-analysis. On September 28, 2026, we checked the adult UC trial’s full-text methods and results, the abstracts of the other studies cited above, and US official guidance. A targeted update search identified the 2026 trial; no exhaustive search or independent pooled analysis was performed. Clinical interpretations remain limited by the access described here.

    Adapted and expanded from the Korean-language Aether Health review. The English edition adds US context and newer research. For background, see our SCFA and fiber guide. The Korean page is optional reading, not a required source for understanding this edition.

    Transparency: Prepared with AI assistance. No independent medical or scientific review is claimed for this English edition. The Korean edition records the operator’s September 24, 2026 disclosure of no current financial interest in related butyrate/SCFA ingredient or product companies. No purchase or affiliate links are included.

    Update history: September 28, 2026 — First English edition; ITT denominators and maintenance endpoint clarified; 2026 IBD trial added.

    Written and edited by: Denny Jaeyong Choi (JD), INSEAD MBA

    Medical information notice: General education, not personal diagnosis, treatment, or dosing advice. Discuss supplements and treatment decisions with your qualified clinician.